CITRuS1: CITRuS Stage 1; Feasibility

Sponsor

Royal Surrey County Hospital NHS Foundation Trust (Other)

Overall Status

Recruiting

CT.gov ID

NCT04697394

Collaborator

National Institute for Health Research, United Kingdom (Other), The Clatterbridge Cancer Centre NHS Foundation Trust (Other)

571

Enrollment

Location

Anticipated Duration (Months)

23.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Bowel cancer is the third most common cancer occurring in the UK. Treatment usually involves surgery, often with chemotherapy or radiotherapy. In some cases radiotherapy can be used instead of surgery, especially if surgery may cause a higher risk of symptoms or a colostomy bag. Currently, the medical team collects information on patients' symptoms before and after treatment by direct questions in a clinic setting. It's recognised that patient-reported symptoms often differ from doctor-documented symptoms. This leads to inaccuracies in doctors' descriptions of the effects of cancer or treatment to patients. Patients told us an accurate description of expected symptoms is important when they are choosing their treatment.

Patient-Reported outcomes measures (PROMs) may help us identify what affects the QoL after treatment and develop ways to improve it. The primary aim of the trial is to evaluate whether patients find it acceptable to use electronic data collection to assess their symptoms. Many bowel cancer patients are elderly and they may find electronic data system collection more challenging. The secondary aim is to identify which symptoms impact QoL. This will lead to the development of treatments to manage these symptoms which will be assessed in CITRuS2.

All patients diagnosed with bowel cancer are entered into the colorectal database to determine the effectiveness of cancer treatments and outcomes. Participants will electronically answer questionnaires at study entry and during follow up. The questions are related to health and well-being with a holistic approach. The questions will take approximately 45 minutes to answer the first time and then 15 minutes thereafter. Following consent, participants gain access to their clinical details on the database. Then they can use a computer, laptop, tablet or smart phone to access a webpage and answer questions at monthly intervals over a 2 year period. Email reminders will be sent to prompt log on.

This may help discover how bowel cancer and its treatment affect patients and their lives. This may help doctors describe the effects of treatment more accurately to future patients. It may also help doctors identify which patients need extra help or support through their treatment. Electronic data may allow patterns to be identified that may not be seen by doctors until a later stage. This may enable earlier treatment resulting in less time with symptoms, which could be physically and economically beneficial.

Condition or Disease	Intervention/Treatment	Phase
Colorectal Cancer

Detailed Description

Currently, the medical team collects information on patients' symptoms before and after cancer treatment in response to direct questioning in outpatient clinics. It's recognised that patient-reported symptoms often differ from doctor-documented symptoms. Over time, this leads to inaccuracies in doctors' descriptions of the effects of cancer or its treatment to patients. Patients told us accurate description of expected symptoms is important when they are choosing which treatment to have.

This study will use an electronic database to allow colorectal cancer patients to view their treatment records. Patients will answer questions at study entry and at set intervals during treatment and follow-up. The questions are related to health and well-being. The questionnaires are patient reported outcome measures (PROMs) which have been used in paper format in trials with many patients internationally.

The information the patients give us will help doctors describe treatment effects more accurately to future patients and to identify patients who may need extra support during or after their treatment. Electronic data collection allows patterns to be identified that may not be seen by doctors until a later stage. The symptoms identified in this study will be used to develop treatments that may benefit future patients. The electronic database will be used identify the need for intervention then to deliver the recommended treatments to patients automatically when they are identified. For example, if questionnaire responses show a patient has an unplanned loss of 3% of their body weight an information sheet on increasing calorie intake and eating well with a small appetite would be emailed to them and a dietician alerted so a follow up call could be made two weeks later.

Study Design

Study Type:

Observational

Anticipated Enrollment :

571 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

To Examine Whether a Complex Intervention Protocol Decreases Toxicity in Patients Following Radiotherapy or Surgery for Colorectal Cancer. Stage 1- Feasibility of Electronic Data Collection

Anticipated Study Start Date :

Apr 25, 2022

Anticipated Primary Completion Date :

Apr 25, 2024

Anticipated Study Completion Date :

Apr 25, 2024

Outcome Measures

Primary Outcome Measures

Ability to complete the web-based electronic questionnaires online outside of the hospital setting. [2 years]
Colorectal patients ability to electronically complete patient reported outcome measures
Continuous retention of patients completing electronic data. [2 years]
Sustained retention of electronic data collection from colorectal patients over a 2 year period

Secondary Outcome Measures

Symptom cluster identification [1 year]
Identification of symptom clusters in the electronic data to use for part 2 of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients diagnosed with colorectal cancer from the 5 participating centres (Guilford, Clatterbridge, Nottingham, Queens Hospital and Hull)
No distant metastases
Patients due to undergo surgery or radiotherapy as a definitive treatment
≥ 18 years of age. No maximum age.
The ability to complete an internet based English written questionnaire either from their home or on a portable electronic device
Patients to have read the patient information sheet and have electronically signed the informed consent
Follow-up in clinic possible

Exclusion Criteria:

Patient choice
< 18 years of age
Evidence of metastatic disease
History of other cancer less than five years ago, excluding non-melanoma skin cancer
Evidence of metastatic disease-patients not undergoing surgery or radiotherapy as a definitive treatment
The inability to complete an internet based English written questionnaire at home or on a portable electronic device
Patient with history of poor compliance or current or past psychiatric conditions that would interfere with compliance to the study protocol or cause further psychological distress.